anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

215,701-215,760 of 319,975

filter-aware
01
Slide 1
The slide features both the Aeglea and Spyre Therapeutics logos, indicating a transition or merger context.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
03
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
04
Includes a footnote regarding a 1-for-25 reverse stock split.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a pipeline chart format to show the development status of seven different programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
06
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
07
The slide uses a donut chart to illustrate market growth from 2021 to 2028.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations 1 hit
08
The chart uses a visual metaphor of an arrow pointing from current standard of care (SOC) to a higher efficacy/convenience target.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
09
The slide uses a numbered list format to present strategic pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)1 hit
10
The slide uses a visual representation of an antibody molecule with callouts to specific engineering improvements, supported by a scatter plot showing clinical precedent for half-life extension.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
11
Uses a visual metaphor of antibody combination to explain the therapeutic strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
12
The slide uses a Venn diagram to represent the intersection of genetic targets and a bar chart to demonstrate the efficacy of patient selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
13
The slide uses a Gantt-style pipeline visualization to show progress of seven distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
14
The slide uses a Gantt-style layout to show progress across Discovery, IND-Enabling, and Clinical stages.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
15
Includes a KOL quote and two charts: a bar chart for global sales and a line chart for market share.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Aha Moment1 hit
16
The chart uses a vertical axis to imply a safety spectrum (Safest to Riskiest) and a horizontal axis for efficacy (clinical remission %).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
17
The slide uses a checkmark/arrow matrix to highlight competitive differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
18
The slide uses a standard antibody diagram to annotate specific engineering improvements.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
19
Includes structural visualization of the epitope and two dose-response curves.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
20
The chart shows dose-response curves for three donors; the table summarizes the calculated EC50 values.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
21
The chart uses a log-linear scale for concentration over time to demonstrate the beta-elimination phase.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
22
The slide uses a bar chart to compare pharmacokinetic properties between a proprietary drug candidate (SPY001) and a competitor (Entyvio).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
23
Uses a visual timeline/comparison to contrast current standard of care with the proposed product.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
25
Data from GEMINI 1 study; highlights that higher exposure does not necessarily correlate with higher remission rates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
26
The slide uses a 2x2 grid to summarize the program's value proposition.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
27
The slide uses peer benchmarking to justify valuation growth expectations based on clinical trial phases.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
28
The table highlights the competitive positioning of SPY001, specifically emphasizing its subcutaneous administration profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
29
The chart compares preference share between Naïve and Switch patients for four different drug profiles.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
30
The slide uses a Gantt-style pipeline visualization to show progress from discovery to clinical stages for seven distinct programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
31
The chart uses a color-coded safety gradient on the Y-axis and efficacy percentages on the X-axis.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
32
The slide uses a checkmark-based comparison matrix to highlight SPY002's superior profile.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
The slide uses an antibody diagram to annotate specific technical improvements (half-life extension and formulation).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide uses a cross-trial comparison to argue that the superiority of one mechanism over the other is not yet established, supporting a redundant development strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
The slide uses two distinct chart types: a dose-response curve (sigmoidal) and a scatter plot to demonstrate potency and specificity.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
The slide uses a 2x2 grid to summarize the program's value proposition.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
The slide uses a mountain-like diagram to represent sequential or cumulative expansion of indications.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
38
The slide uses a Gantt-style visualization to show the progression of various IBD programs.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
39
The slide uses a biological process diagram to illustrate the mechanism of action for three distinct drug candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
40
The slide uses a bar chart to illustrate the additive effect of combining two therapies, with a supporting table for N, maintenance remission, and safety.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
41
The slide uses a comparison framework to highlight the competitive advantage of Spyre's gut-selective approach.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
42
The slide uses a process flow diagram to illustrate the clinical trial strategy for SPY001 and SPY003.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
43
The slide uses a visual representation of a bispecific or combination antibody structure.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
44
The slide uses a Venn diagram to show target overlap and a hierarchical tree diagram to show diagnostic-driven treatment selection.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
45
The slide uses a comparative bar chart structure to validate the efficacy of genetic companion diagnostics (CDx) in improving clinical outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
46
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
47
The slide includes a section for Management team and a section for Board of Directors, with headshots and titles for each individual, followed by a logo grid of affiliated organizations.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
48
The slide uses a table-based timeline structure to map drug candidates (SPY001-004) against expected clinical milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
49
The slide uses a custom bar chart visualization within a table to show market cap ranges (Min, IPO, Today, Max).Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
50
The table maps historical M&A deal values to Spyre's internal pipeline milestones.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
51
Aeglea BioTherapeutics | Investor Presentation Deck | 56 slidesAeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
52
The slide highlights the partnership with Paragon Therapeutics, detailing its founding, team size, operational capacity, program count, and the spin-out of Apogee Therapeutics.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a series of icons to represent different scientific methodologies.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
54
The central graphic is an antibody structure inside a pentagon, representing the five optimization pillars.Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
12
Yatsen | Results Presentation Deck | 17 slidesYatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
13
The slide explains the drivers behind the financial performance metrics.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
14
The chart shows a breakdown of R&D, G&A, S&M, and Fulfillment expenses.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
15
The slide provides a detailed breakdown of adjustments made to GAAP net income to arrive at non-GAAP figures, including share-based compensation, amortization, and investment revaluations.Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
16
The chart displays two distinct metrics: a running balance (top row) and quarterly cashflow (bars).Yatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit
17
Yatsen | Results Presentation Deck | 17 slidesYatsen | Results Presentation Deck | 17 slides · Yatsen Holding Limited
Conference presentation Investor relations Beat · Action1 hit